OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for TL304270V

Neuronal membrane glycoprotein M6 a (GPM6A) Human shRNA Lentiviral Particle (Locus ID 2823)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Neuronal membrane glycoprotein M6 a (GPM6A) Human shRNA Lentiviral Particle (Locus ID 2823)
Locus ID:	2823
Synonyms:	GPM6; M6A
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	GPM6A - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	NM_001261447, NM_001261448, NM_005277, NM_201591, NM_201592, NR_048571, NM_201591.1, NM_201591.2, NM_005277.1, NM_005277.2, NM_005277.3, NM_005277.4, NM_201592.1, NM_201592.2, NM_001261447.1, BC022508, BC022508.1, BC022528, BC022528.1, BC010461, BC032904, BC037853, BC044612, BC053954
UniProt ID:	P51674
Summary:	Involved in neuronal differentiation, including differentiation and migration of neuronal stem cells. Plays a role in neuronal plasticity and is involved in neurite and filopodia outgrowth, filopodia motility and probably synapse formation. GPM6A-induced filopodia formation involves mitogen-activated protein kinase (MAPK) and Src signaling pathways. May be involved in neuronal NGF-dependent Ca(2+) influx. May be involved in regulation of endocytosis and intracellular trafficking of G-protein-coupled receptors (GPCRs); enhances internalization and recycling of mu-type opioid receptor.[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

View online »

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).